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Abstract: Elevated serum phosphate levels as a consequence of chronic kidney disease (CKD) 
contribute to the increased cardiovascular risk observed in dialysis patients. Protein restric-
tion and dialysis fail to adequately prevent hyperphosphatemia, and in general treatment with 
oral phosphate binding agents is necessary in patients with advanced CKD. Phosphate plays 
a pivotal role in the development of vascular calciﬁ  cation, one of the factors contributing to 
increased cardiovascular risk in CKD patients. Treatment of hyperphosphatemia with standard 
calcium-based phosphate binders and vitamin D compounds can induce hypercalcemic episodes, 
increase the Ca × PO4 product and thus add to the risk of ectopic mineralization. In this review, 
recent clinical as well as experimental data on lanthanum carbonate, a novel, non-calcium, 
non-resin phosphate binding agent are summarized. Although lanthanum is a metal cation no 
aluminium-like toxicity is observed since the bioavailability of lanthanum is extremely low 
and its metabolism differs from that of aluminium. Clinical studies now document the absence 
of toxic effects of lanthanum for up to 6 years of follow-up. The effects of lanthanum on bone, 
vasculature and brain are discussed and put in perspective with lanthanum pharmacokinetics.
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Introduction
Chronic kidney disease (CKD) and renal function decline are from an early stage on 
accompanied by disturbances in mineral metabolism, driven by increased parathyroid 
hormone (PTH) secretion and decreased production of active vitamin D. Impaired 
phosphate excretory capacity eventually results in positive phosphate balance and 
hyperphosphatemia, which in combination with low serum levels of ionized calcium due 
to lack of vitamin D, contributes to the development of secondary hyperparathyroidism 
and metabolic bone disease. Chronically increased parathyroid gland stimulation may 
eventually lead to parathyroid gland hyperplasia and tertiary hyperparathyroidism, ie, 
autonomous, unregulated PTH production and secretion.1,2
The mineral phase of bone, hydroxyapatite, is the body’s largest phosphate store, 
but inorganic phosphate, in ATP, plays an important role in cellular energy storage 
and phosphorylation and dephosphorylation of proteins are key events in numerous 
cellular singalling pathways. Serum phosphate levels above 6.5 mg/dL and elevated 
Ca × PO4 product in serum (72 mg²/dL²) are associated with a signiﬁ  cantly increased 
mortality risk.3 Even mild increases in serum phosphate within the normal range are 
associated with a signiﬁ  cant increase in mortality risk.4 Phosphate retention mainly 
increases cardiovascular mortality, such as death through coronary artery disease as 
well as sudden death.5 Disturbed phosphate metabolism is associated with increased 
cardiovascular mortality risk in CKD patients, and a causal role for hyperphosphatemia 
in the development of vascular calciﬁ  cation, a characteristic feature of cardiovascular 
disease in uremic patients, has been demonstrated both experimentally and in vitro.6,7 International Journal of Nephrology and Renovascular Disease 2009:2 2
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Calciﬁ  cation of the abdominal aorta was shown to predict 
subsequent cardiovascular events in hemodialysis patients8 
as well as in the general population.9
Treatment of hyperphosphatemia
Dietary protein is the main source of phosphate intake, 
but limiting protein intake is often insufﬁ  cient to prevent 
phosphate accumulation and the subsequent development of 
hyperphosphatemia. Moreover, protein restriction can con-
tribute to malnutrition, thereby increasing the mortality risk in 
CKD patients.10,11 However, a recent randomized controlled 
trial showed signiﬁ  cant reduction in serum phosphate with 
protein restriction to 0.55 g/kg/day without increased risk for 
malnutrition.12 Renal replacement therapy also provides inad-
equate removal of the excess phosphate load in patients with 
end-stage renal failure, mainly because most phosphate is in 
the cellular compartment and exchange between the intra-
cellular and extracellular compartments is rate-limiting.13,14 
Therefore, additional treatment with phosphate binding agents 
is necessary in most dialysis patients, and is recommended 
even in CKD stages 3 and 4 when hyperphosphatemia is not 
under control with protein restriction. Phosphate binders are 
administered orally and prevent phosphate absorption from 
the gastrointestinal tract by forming insoluble complexes 
with phosphate in the gut.
The ﬁ  rst phosphate binder, aluminium hydroxide, was 
introduced in the seventies. This very efﬁ  cient phosphate 
binder was abandoned in favor of calcium-containing phos-
phate binders such as calcium carbonate and calcium acetate 
because of its signiﬁ  cant negative effects on bone metabolism 
and cognitive function.
Calcium-based phosphate binders have replaced 
aluminium as standard phosphate binder therapy. They bind 
phosphate in a pH-dependent way, with calcium acetate being 
more efﬁ  cient than calcium carbonate. The amount of calcium 
absorbed per amount of phosphate bound is also lower with 
calcium acetate.15,16 The absorption of a substantial proportion 
(30%–40%) of the elemental calcium administered with these 
compounds was initially not considered to be problematic, 
as calcium levels tend to be low in uremic patients due to 
lack of active vitamin D. Low serum ionized calcium is the 
most important driving force for PTH secretion, thus, cal-
cium-based binders also limit the development of secondary 
hyperparathyroidism.
In recent years, however, several epidemiological studies 
revealed an association between hypercalcemia or hypercal-
cemic episodes and cardiovascular mortality risk. In addition 
to hyperphosphatemia, hypercalcemia and elevated serum 
Ca × P product were identiﬁ  ed as factors contributing to the 
development of uremia-related vascular calciﬁ  cation.17–21
Although calcium-based phosphate binders are still 
considered the standard treatment for hyperphosphatemia 
in chronic and end-stage renal failure, the more recent 
calcium-free phosphate binders sevelamer hydrochloride 
and lanthanum carbonate control phosphate levels without 
inducing calcium overload and should be considered for 
patients developing hypercalcemia when given calcium-
based binders.
Sevelamer hydrochloride is a non-aluminium, non-
calcium-containing hydrogel of cross-linked poly-[allylamine 
hydrochloride] that binds phosphate anions through ionic 
exchange with chloride. In comparison with calcium-based 
phosphate binder therapy, treatment with sevelamer slowed 
down the progression of coronary artery and aortic calciﬁ  -
cation in dialysis patients,22–25 although Barreto et al26 did 
not observe this effect in the BRiC study. Apart from its 
phosphate binding activity, sevelamer also acts as a bile 
acid sequestrant,27 resulting in lowering of total and LDL 
cholesterol, and may induce acidosis due to exchange of 
bicarbonate for chloride.28,29 These non-phosphate-related 
effects of sevelamer may also have an impact on the vascular 
outcome.
In a systematic review of the efﬁ  cacy and safety of 
established phosphate binders Sprague concluded that cal-
cium carbonate, sevelamer hydrochloride and lanthanum 
carbonate are all effective as phosphate binders. Drawback of 
calcium carbonate is the induction of hypercalcemia, whereas 
sevelamer contributes to acidosis and does not bind phosphate 
efﬁ  ciently in acidic environment. In comparison, lanthanum 
treatment imposes a lower pill burden, which possibly is 
associated with increased patient compliance.30
Lanthanum pharmacokinetics
Lanthanum is a rare earth element belonging to the 
‘lanthanide’ elements. It is the most electropositive 
(cationic) element of the rare earth group, is uniformly 
trivalent, and almost exclusively engages in ionic binding. 
It is a hard ‘acceptor’ with an overwhelming preference for 
oxygen-containing anions. Therefore, the most common 
biological ligands are the carboxyl and phosphate groups 
(PO4
3–) with which it can form very tight complexes. These 
chemical characteristics form the basis for the suitability of 
lanthanum carbonate as a phosphate binder.
The introduction of yet another metal as a phos-
phate binder agent prompted concern for the potential 
aluminium-like toxic effects of lanthanum carbonate on bone International Journal of Nephrology and Renovascular Disease 2009:2 3
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and brain. However, lanthanum pharmacokinetics differ 
substantially from the pharmacokinetic proﬁ  le of aluminium, 
as illustrated in Figure 1. In contrast with aluminium, accu-
mulation of lanthanum in the context of impaired renal func-
tion is low because ﬁ  rstly, the absorption and bioavailibility 
of lanthanum are extremely low, and secondly, the very small 
absorbed fraction is mainly cleared via biliary excretion, with 
renal clearance of lanthanum being almost negligible.31
In a phase I study the absolute bioavailability of 
lanthanum after a single oral dose was shown to be 
0.00127% ± 0.00080%. Renal clearance was very low 
following oral administration (1.36 ± 1.43 mL/min) 
amounting to 1.7% of total plasma clearance.32 The majority 
of an oral lanthanum dose is excreted in the feces. Biliary 
elimination (80%) and direct transport across the gut wall into 
the lumen (13%) represent the main routes of elimination. 
Therefore, the elimination of lanthanum is not dependent 
on renal function. So CKD patients are not at an increased 
risk for accumulation of the element. Moreover, lanthanum 
pharmacokinetics in CKD 5 patients and subjects with normal 
renal function were comparable.33 Plasma lanthanum is almost 
completely protein bound, leaving plasma concentrations of 
free lanthanum below 3 pg/mL.33
In contrast, absorption of orally administered aluminium 
from the gastrointestinal tract amounts from 0.01% to 0.10% 
(Figure 1).34,35 In addition, aluminium is mainly eliminated 
via the kidney, with negligible biliary excretion. When 
aluminium hydroxide (2.4 g/day) was co-administered with 
citrate, aluminium excretion increased from 70 to 120 mg/day 
up to 350 to 603 mg/day,35 whereas gastro-intestinal absorp-
tion of lanthanum is not inﬂ  uenced by citrate.
Lanthanum as a phosphate binder
Lanthanum binds phosphate with high afﬁ  nity and indepen-
dent of pH. Lanthanum is therefore able to effectively bind 
phosphate before it is absorbed in both the acidic environ-
ments of the stomach and proximal small intestine, as well 
as more distally in the gastrointestinal tract.36
In short-term placebo-controlled studies 4 weeks of 
treatment with lanthanum carbonate resulted in signiﬁ  cantly 
lower phosphate and Ca × P product levels in hemodialysis 
and CAPD patients.37–39 Lanthanum carbonate has been 
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Figure 1 Comparison of the pharmacokinetics of aluminium and lanthanum. In contrast to aluminium, there is no increased deposition of lanthanum in CKD compared to 
patients with normal renal function, as the fraction of lanthanum absorbed in the gut is much lower, and lanthanum elimination is independent of renal function as it is mainly 
eliminated via the bile.   Adapted with permission from Persy VP et al. Semin Dial. 2006;19(3):195–199.59 Copyright © 2006 Blackwell Publishing.
Abbreviations: ESRF, end stage renal failure.International Journal of Nephrology and Renovascular Disease 2009:2 4
Persy et al
available for clinical use since 2004 and the additional studies 
and prolonged follow up described since then indicate that 
lanthanum carbonate also provides good long-term phosphate 
control. Follow up data from a 6-month comparative trial 
with calcium carbonate, showing comparable phosphate 
control without hypercalcemia under lanthanum carbonate, 
have been reported after 1 year,40 3 years41 and recently also 
after 6 years,42 demonstrating adequate and safe long-term 
phosphate control with lanthanum carbonate. Finn et al 
demonstrated adequate phosphorus control with PTH levels 
within the National Kidney Foundation Kidney Disease 
Outcomes Quality Initiative (K/DOQI) guideline range over 
a 2-year period.43 A double blind RTC comparing lanthanum 
and calcium carbonate reported similar phosphate control but 
signiﬁ  cantly lower increase in serum calcium in lanthanum 
treated dialysis patients.44
In a placebo-controlled study in CKD 3 and 4 patients, 
the proprortion of patients achieving serum phosphorus 
levels 4.6 mg/dL was not signiﬁ  cantly different between 
both groups, but serum phosphorus and iPTH levels in 
lanthanum treated patients were signiﬁ  cantly lower.45
Lanthanum carbonate being a non-calcium phosphate 
binder, together with clinical evidence indicating that 
lanthanum treatment does not induce hypercalcemia and 
decreases the serum Ca × P product as cited above, gives 
rise to the hypothesis that lanthanum carbonate treatment 
may also have a beneﬁ  cial impact on the progression of 
vascular calciﬁ  cation. To date, no clinical data on the effect 
of lanthanum carbonate treatment on vascular calciﬁ  cation 
have been reported, but in rats with adenine-induced chronic 
renal failure, treatment with 2% lanthanum carbonate via the 
diet attenuated the development of uremia-related vascular 
calciﬁ  cation.46
Effects of lanthanum on bone
Previous experience with aluminium, which dramatically 
affected bone health, inducing mainly osteomalacia and 
adynamic bone disease, prompted concern about the accumu-
lation in and potential toxic effects of lanthanum on bone. In 
the mean time, extensive research has proven that lanthanum 
accumulation in bone is limited and does not induce any 
aluminium-like effects.
In rats with normal renal function long-term administration 
of lanthanum carbonate at doses up to 2000 mg/kg per 
day had no effect on bone,47 while loading chronic renal 
failure rats with lanthanum carbonate doses of 1000 to 
2000 mg/kg per day for 12 weeks induced impairment of 
bone mineralization.48 However, further investigation clearly 
proved that phosphate depletion induced by high doses of 
lanthanum carbonate was the mechanism behind this effect 
on bone. Comparable mineralization defects were observed 
in rats treated with equivalent doses of sevelamer,49 and 
in rats maintained on a low phosphorus diet.50 Moreover, 
the lanthanum-induced bone effects were normalized by 
phosphate repletion.50 In remnant kidney rats lanthanum 
carbonate-induced mineralization defect occurred within 
2 weeks of treatment, and was rapidly reversible upon 
lanthanum withdrawal. No correlation between impaired 
mineralization and bone lanthanum levels was observed, 
as the bone lanthanum concentration was not yet increased 
after 2 weeks of treatment and decreased rather slowly after 
lanthanum withdrawal.51
In incipient dialysis patients bone lanthanum concentration 
rose from 0.05 ± 0.03 to 2.3 ± 1.6 μg/g over a 1-year treatment 
period with lanthanum carbonate, while during the subsequent 
2 year washout period bone lanthanum levels slightly 
decreased again to 1.9 ± 1.6 μg/g.52 In prevalent dialysis 
patients, bone lanthanum levels did not exceed 5.5 μg/g 
wet weight (median 1.8 μg/g) after 1 year of treatment with 
lanthanum carbonate.53 In a model of bone lanthanum kinetics 
based upon data from pharmacokinetic data from healthy 
volunteers and bone biopsy data from patients treated with 
lanthanum carbonate for up to 5 years, the initial deposition 
rate of lanthanum in bone was calculated to be 1 μg/g/year 
resulting in an extrapolated 7-fold increase in total bone 
lanthanum after 10 years of treatment. This model further 
predicts lanthanum clearance from bone at a rate of 13% per 
year after cessation of treatment.54
Two clinical studies document the absence of adverse 
effects of lanthanum carbonate treatment on bone histology.53,55 
In a randomized, parallel-group, open-label study the evo-
lution of renal osteodystrophy (ROD) in dialysis patients 
receiving either lanthanum carbonate or calcium carbonate 
was compared after histomorphometric examination of paired 
bone biopsies53 after 1 year of treatment. While baseline 
bone histology was comparable between both groups with 
mixed ROD as the most common type of bone lesion, 1 year 
of lanthanum carbonate treatment tended to normalize bone 
histology, with reduced prevalence of the more extreme 
forms of ROD (hyperparathyroidism, adynamic bone 
disease and osteomalacia). Calcium carbonate treatment was 
associated with an increase in the proportion of patients with 
hyperparathyroidism or adynamic bone disease. Overall, 
5 out of 7 (71%) of lanthanum carbonate-treated patients with 
low-turnover bone disease (adynamic bone or osteomalacia) 
at baseline, and 80% (4 out of 5) of those with baseline International Journal of Nephrology and Renovascular Disease 2009:2 5
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hyperparathyroidism evolved towards a normalization in 
bone turnover, compared with 3 out of 7 (42%) and 3 out 
of 6 (50%) of calcium carbonate-treated patients, respec-
tively.53 In a prospective, open-label study during which 
patients on dialysis were randomized to lanthanum carbonate 
treatment or continuation of their previous phosphate binder, 
a signiﬁ  cant improvement in bone turnover after 1 year 
and in bone volume after 2 years of treatment was seen in 
the lanthanum carbonate group, whereas these parameters 
remained unchanged in patients treated with standard phos-
phate binder therapy. Bone histomorphometric parameters 
did not correlate with bone lanthanum concentrations.55
In contrast to aluminium-related bone disease which 
is characterized by decreased osteoblast number and/or 
activity,56 no adverse effect of lanthanum carbonate on 
osteoblasts has been observed in either rats or humans. 
In contrast, Wang et al recently reported that lanthanum 
promoted osteoblast differentiation in vitro, resulting in 
increased expression of osteoblast differentiation factors 
such as core binding factor-1 (cbfa-1), alkaline phosphatase, 
osteopontin, bone sialoprotein and osteocalcin, as well as 
increased matrix mineralization.57 This effect was mediated 
by increased phosphorylation of extracellular signal-related 
kinase (ERK).57
Toxic effects strongly depend on local concentrations in 
target tissue and cells, whereas physicochemical interference 
with mineralization on the level of hydroxyapatite nucleation, 
crystal growth or structure strongly depends on the molar 
ratio of an element over calcium. Lanthanum localization 
studies have not revealed any indication that lanthanum 
would selectively concentrate at particular sites or cell types 
in bone. Localization of lanthanum carbonate in bone with 
micro X-ray ﬂ  uorescence demonstrated the presence of 
lanthanum at both active and quiescent trabecular surface, 
independent of the type of underlying ROD. In addition, 
lanthanum could be detected distributed diffusely throughout 
the mineralized matrix, especially in subjects with increased 
bone turnover, and concentrated close to resorption lacunae, 
probably in osteoclasts or macrophages (Figure 2).58
Additionally, based upon a bone lanthanum concentration 
of 9.5 μg/g wet weight (67 nmol/g) – the highest lanthanum 
concentration observed in the bone of dialysis patients after 
4.5 years of treatment with 2.5 to 3.0 g lanthanum/day – with 
bone calcium concentration at 120 mg/g (3 mmol/g) and 
assuming a homogeneous distribution of lanthanum through-
out the bone, the molar bone lanthanum/calcium ratio would 
be as low as 2 × 10–5, ie, only 1 out of 50,000 calcium atoms 
would be replaced by lanthanum, making physicochemical 
interference of lanthanum ions incorporated into the bone 
matrix with the mineralization process highly unlikely. 
For comparison, according to the same premisses the 
molar aluminium/calcium ratio was estimated at 6 × 10–2, 
indicating that 1 out of 16 calcium atoms would be replaced 
by aluminium.59
Effects of lanthanum on the liver
In addition to bone, lanthanum deposition is also detected 
in the liver. This is not surprising, as lanthanum is mainly 
excreted via the hepatobiliary pathway (Figure 1). Hence, 
CKD patients are not expected to be at an increased risk for 
accumulation of lanthanum in comparison with subjects with 
normal renal function.
In line with these expectations, clinical experience 
with lanthanum carbonate as a phosphate binder up to now 
provided no indications for any hepatotoxic effect of this 
compound.42 Over 6 years of follow up, liver enzymes did 
not increase and the limited number of liver or biliary related 
adverse events were mainly observed in the ﬁ  rst 2 years of 
treatment and none of them were considered to be related to 
lanthanum treatment.42
However, increased liver lanthanum deposition after oral 
lanthanum loading in uremic rats in comparison with normal 
renal function rats was observed in two different experimental 
models of chronic renal failure.60,61 After intravenous 
Figure 2 Schematic representation of lanthanum localization in bone. With micro 
X-ray ﬂ  uorescence, lanthanum was found at active bone formation and resorption 
sites, as well as on quiescent bone surfaces and dispersed throughout the mineralized 
matrix. Lanthanum concentrations in proximity to resorption lacunae probably reﬂ  ect 
lanthanum uptake in osteoclasts or macrophages.58 Adapted with permission from Persy 
VP et al. Semin Dial. 2006;19(3):195–199.59 Copyright © 2006 Blackwell Publishing.International Journal of Nephrology and Renovascular Disease 2009:2 6
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lanthanum administration, liver lanthanum concentrations 
were independent of renal function, indicating comparable 
lanthanum elimination, and indirectly pointing towards 
increased absorption of lanthanum from the gastrointestinal 
tract as explanation for differences in liver tissue deposition 
in normal versus uremic rats.62 Oral lanthanum carbonate 
loading (1000 mg/kg per day – 6 days per week) of rats 
with moderately impaired renal function resulted in liver 
lanthanum concentrations consistently below 3 μg/g reaching 
a plateau after 6 weeks of lanthanum treatment,62 indicating 
that a steady state of liver lanthanum concentration is reached 
at that time point.
To enable subcellular localization of lanthanum in 
liver tissue, rats received daily intravenous injections 
with 0.3 mg/kg lanthanum chloride for 4 weeks, lead-
ing to liver lanthanum concentrations of 30 to 50 μg/g 
(10- to 20-fold higher than values seen after oral lanthanum 
loading). Sensitive techniques such as transmission elec-
tron microscopy (TEM), Energy dispersive X-ray analysis 
(EDX) and electron loss spectroscopy (EELS) were used 
to demonstrate that lanthanum in the liver of these animals 
was present in the lysosomes of hepatocytes, with most 
of the lanthanum concentrated in the biliary pole of the 
hepatocyte and within bile canaliculi. No lanthanum 
could be detected in hepatocyte mitochondria, nucleus or 
cytoplasm (Figure 3).63
Lanthanum and brain
In contrast to aluminium, lanthanum does not pass the 
blood–brain barrier. In several experimental studies, 
lanthanum concentrations in the brain after intravenous 
lanthanum dosing at 30 to 300 mg/kg/day for 4 weeks or 
oral gavage at 1500 mg/kg/day were below the limit of 
quantiﬁ  cation, ie, 6 ng/g.
Assessment of cognitive function of patients after 2 years 
of treatment in a randomized open-label study comparing 
lanthanum carbonate with standard treatment revealed that 
cognitive function deteriorated with time in both groups. 
Overall cognitive function was comparable between both 
treatments, with lanthanum-treated patients showing a small 
hepatocyte
hepatocyte
bile canaliculus
tight junction
La
La
La
hepatocyte
hepatocyte
La
La
La
La La
La La
La La
Figure 3 Lanthanum is localized in lysosomes at the biliary pole of hepatocytes.   Transmission electron microscopy image of liver tissue of La loaded rat (dose: 0.3 mg/kg/day 
IV, 4 weeks) showing electron dense precipitates displaying a crystalline granular structure within the lysosomes and bile canaliculus. The presence of lanthanum in these 
granular structures was evidenced by electron energy loss spectroscopy (EELS).   Adapted with permission from Macmillan Publishers, Ltd. Kidney Int. Bervoets AR, Behets GJ, 
Schryvers D, et al. 2009;75(4):389–398. Copyright © 2008.62International Journal of Nephrology and Renovascular Disease 2009:2 7
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but signiﬁ  cant improvement in numeric working memory, of 
which the clinical signiﬁ  cance remains to be determined.64
Summary
Clinical data for up to 6 years of follow-up indicate that 
lanthanum carbonate is an effective and safe non-calcium 
phosphate binder. Concerns about aluminium-like toxicity of 
lanthanum carbonate have effectively been countered by (i) 
pharmacokinetic studies indicating that lanthanum is mainly 
eliminated via the liver, (ii) bone studies showing hetero-
geneous localization of lanthanum in bone and the absence 
of adverse effects on bone histology in lanthanum-treated 
patients, (iii) no adverse effect of lanthanum treatment on 
cognitive functioning and absence of lanthanum deposition 
in brain tissue.
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